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1Abstract
Background  Cardiac  autonomic  dysfunction  manifests  as  reduced  heart  rate
variability (HRV) in idiopathic Parkinson’s disease (PD), but no significant reduction
has been found in PD patients who carry the  LRRK2 mutation. Novel HRV features
have  not  been  investigated  in  these  individuals.  We  aimed  to  assess  cardiac
autonomic modulation through standard and novel approaches to HRV analysis in
individuals who carry the LRRK2 G2019S mutation.
Methods Short-term electrocardiograms were recorded in 14 LRRK2-associated PD
patients, 25 LRRK2-non-manifesting carriers, 32 related non-carriers, 20 idiopathic
PD patients, and 27 healthy controls. HRV measures were compared using regression
modeling,  controlling  for  age,  sex,  mean  heart  rate,  and  disease  duration.
Discriminant  analysis  highlighted  the  feature  combination  that  best  distinguished
LRRK2-associated PD from controls.
Results  Beat-to-beat  and  global  HRV  measures  were  significantly  increased  in
LRRK2-associated PD patients compared to controls (e.g., deceleration capacity of
heart rate: p=0.006) and idiopathic PD patients (e.g., 8th standardized moment of the
heartbeat  interval  distribution:  p=0.0003),  respectively.  LRRK2-associated  PD
patients also showed a significantly increased irregularity of heart rate dynamics, as
quantified by Rényi entropy, when compared to controls (p=0.002) and idiopathic PD
patients (p=0.0004). Ordinal pattern statistics permitted the classification of LRRK2-
associated PD individuals with 93% sensitivity and 93% specificity. Consistent results
were  found  in  a  subgroup  of  LRRK2-non-manifesting  carriers  when  compared  to
controls.
Conclusions  Increased  beat-to-beat  HRV  in  LRRK2 G2019S  mutation  carriers
compared  with  controls  and  idiopathic  PD  patients  may  indicate  an  augmented
cardiac autonomic  cholinergic  activity,  suggesting an early  impairment of  central
vagal feedback loops in LRRK2-associated PD.
Keywords Autonomic  dysfunction,  heart  rate  variability,  Parkinson’s  disease,  LRRK2,
deceleration capacity of heart rate, Rényi entropy
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2Parkinson’s disease (PD) is a progressive multisystem degenerative process, involving motor
and  non-motor  dysfunction  associated  with  multiple  neuroanatomical  areas,
neurotransmitters,  and protein aggregates  (Kalia & Lang,  2015).  Symptoms and signs of
autonomic dysfunction are common in idiopathic PD (iPD) and cardiac dysautonomia has
been demonstrated by several measures from autonomic reflex tests to heart rate variability
(HRV) analysis, all of which have consistently revealed a decreased HRV in iPD (Kallio et al.,
2000; Maetzler et al., 2015; Rodriguez et al., 1996; Turkka et al., 1987). However, the effect
of  LRRK2  mutations,  the most  common monogenic cause of  PD  (Healy et  al.,  2008),  on
autonomic function is still debated.
The most  common  mutation  in  the  gene encoding  leucine-rich  repeat  kinase  2 (LRRK2)
results  in  a  G2019S amino acid  substitution,  which  increases  the  kinase  activity  of  the
protein (West et al., 2005). Symptoms of dysautonomia are frequent in LRRK2-associated PD
(LRRK2-PD)  (Tijero et al.,  2013), although differences in non-motor symptoms have been
found between LRRK2-PD and iPD patients. Some of us have previously found no significant
alterations  in  cardiac  autonomic  modulation  in  LRRK2 G2019S  (NM_198578.3  (LRRK2):
c.6055G>A, p.Gly2019Ser) mutation carriers, as assessed by traditional time and frequency
domain  HRV  analysis  (Visanji  et  al.,  2017),  although  others  have  indicated  significant
modifications in some frequency domain measures (Solla, 2013). Thus, the involvement and
timing of cardiac autonomic alterations over the course of LRRK2-PD remain unclear and the
extent of dysautonomia is not fully understood.
This  study  aimed  to  assess  cardiac  autonomic  modulation  through  standard  and  novel
approaches to HRV analysis in individuals who carry the LRRK2 G2019S mutation. The new
approaches  quantify  the  complex,  non-stationary  dynamics  of  heart  rate  (HR)  and  may
therefore  provide  clinically  relevant  information  that  cannot  be  captured  by  traditional
methods.  Early  recognition  of  autonomic  impairment  would  potentially  allow  timely
therapeutic  intervention  and  could  positively  impact  disease  course,  thereby  improving
patient quality of life and decreasing the social cost of PD. Furthermore, early biomarkers of
prodromal PD are needed in preparation for the eventual application of disease-modifying
therapies for LRRK2-PD.
Methods
Subjects
We  studied  14  LRRK2-PD  patients,  25  LRRK2-non-manifesting  carriers  (LRRK2-NMC),  32
related non-carriers (RNC) (non-manifesting family members without the  LRRK2 mutation),
20  iPD  patients,  and  27  unrelated  healthy  controls.  Probands  with  LRRK2 p.G2019S
mutations, iPD patients and healthy individuals (without neurologic disease or family history
of PD) were recruited at the Toronto Western Hospital (Ontario, Canada) and the Parkinson’s
Institute (California, USA). Family members of participants with the LRRK2 mutation and iPD
were also invited to participate. The presence or absence of p.G2019S was evaluated in all
participants  as  previously  described  (Paisan-Ruiz  et  al.,  2005).  Subjects  with  iPD  were
defined  as  individuals  with  PD,  according  to  clinical  diagnosis  by  a  movement  disorder
specialist,  in  the  absence  of  a  family  history  of  the  disease  in  first-  or  second-degree
relatives.  The  study  protocol  was  approved  by  the  University  Health  Network  Research
Ethics  Board  (Toronto)  and  El  Camino  Hospital  Institutional  Review  Board  (Parkinson’s
Institute) and all participants provided written informed consent.
Clinical evaluation
Clinical  evaluation  included  a  neurological  examination,  standardized  videotaping  of  the
neurological  examination, the Unified Parkinson’s Disease Rating Scale part 3 (UPDRSIII),
and  the  Scales  for  Outcomes  in  PD-Autonomic  (SCOPA-AUT).  Individuals  taking  anti-
cholinergics, sympathetic agonists, or sympathetic antagonists or with evidence of thyroid
dysregulation or diabetes were excluded from the study. Assessments were performed by
experienced movement disorders clinicians blinded to genetic status as described previously
(Marras et al., 2011). All participants with PD met UK Parkinson’s Disease Society Brain Bank
Clinical Diagnostic Criteria (Hughes et al., 1992). 
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3Electrocardiographic recording and heartbeat intervals 
Following  five  minutes  of  inactivity  in  a  supine  position,  7-minute  resting  4-lead
electrocardiograms (EKGs) (aVR, aVL, N, aVF) were collected during daylight hours in a non-
fasting state, and digitized at 500 Hz using a laptop-based cardio-card EKG system (Nasiff
Associates,  Inc.,  Central  Square, New  York).  Normal-to-normal  (NN)  cardiac  interbeat
intervals  were  extracted  from  the  EKG  recording  using  Physionet  WAVE  v6.11
(www.physionet.org) in a Unix environment. The EKGs were manually checked for ectopic
beats and regions of  noise that were manually removed, following the application of  an
automated algorithm for obtaining NN interval data (Machado et al., 2000). 
HRV analysis
Sequences of 300 NN intervals were analyzed, unless otherwise stated, using traditional and
novel  HRV  methods  (Supplementary  Fig.  1). See  Electronic  Supplementary  Material  for
further details.
Time domain methods. These measures included the standard deviation of the NN intervals
(SDNN), the width of NN interval distribution (W, difference between the longest and shortest
NN intervals), the coefficient of variation of the NN intervals (CV), the square root of the
mean of the sum of the squares of differences between adjacent NN intervals (rMSSD), the
first order autocorrelation coefficient (r1), the autonomic stress index (ASI) (see  Electronic
Supplementary  Material),  and  the  standardized  central  moments  of  order  m=3–9 of  NN
interval distribution. 
Frequency domain methods.  The power spectral  density was calculated over NN interval
sequences  of  215  seconds  for  the  low  frequency  band  (LF)  (0.04–0.15  Hz),  the  high
frequency band (HF) (0.15–0.4 Hz), and the total spectral power band (TP) (see  Electronic
Supplementary Material). The LF⁄HF ratio, was also determined. 
Information domain methods. The irregularity of NN intervals was determined by Shannon
entropy (ShE), Rényi entropy (RE) and permutation entropy (PE), each of which distinguishes
random  from regular  HR  changes  (Bandt  &  Pompe,  2002;  Cornforth  et  al.,  2014).  ShE
considers the probability of any NN value to appear in the data sequence. RE generalizes
ShE to include measures at different scales (order α), and considers the probability of NN
sequences of different length (λ) to appear in the HR signal. PE considers the probability of
ordinal patterns (P) of different length (λ) occurring over different time scales (τ) of the HR
signal. 
Phase-rectified signal averaging (PRSA). The PRSA algorithm is based on averaging NN data
segments around NN intervals previously defined as anchors (events that trigger particular
HR changes), to quantify the average deceleration and acceleration capacity of HR (DC and
AC, respectively) (Bauer et al., 2006).
Poincaré plot features. Additionally, we examined the standard deviation along the identity
line (SD2) of an ellipse fitted to the scatterplot of each NN interval vs. the next, the standard
deviation perpendicular to the ellipse identity line (SD1), and the SD2/SD1 ratio. 
Statistical analysis
Statistical  analyses  were  performed  using  STATISTICA  software  (StatSoft,  Inc.,  Tulsa,
Oklahoma).  Continuous  variables  were  assessed  for  normality  by  a  Kolmogorov-Smirnov
test, and were logarithmically transformed (Log) to adjust for skewness, except for the HRV
feature r1 which was transformed as: 0.5*Log((1+r1)/(1-r1)). Group differences in HRV were
assessed using multiple linear regression analysis, adjusted for age, sex, and mean HR. The
LRRK2-PD vs. iPD contrast was also adjusted for disease duration. PE contrasts between age-
and sex-matched groups were assessed using a Mann-Whitney U test, whereas a t-test was
applied for contrasting the remaining continuous variables. Sex differences between groups
were assessed using the Chi-Square test. Differences in the distribution of variables were
assessed  through  a  Kolmogorov-Smirnov  test.  Pearson  r  or  Spearman  R  correlation
coefficients were also determined.
Linear discriminant analysis was performed to identify the feature combination with the best
discriminative  power  between  groups,  following  a  forward  stepwise  variable  selection
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4procedure. Candidate features were extracted from a randomly-selected training sample,
where  the  discriminant  models  were  also  estimated.  The  predictive  accuracy  of  the
classification functions was assessed in the remaining test sample with no overlap of cases.
Participants in both training and test subsamples were age- and sex-matched. HRV values
were standardized (Z-scores)  considering the mean value adjusted for age, sex,  and HR
through  multiple  regression  analysis,  for  those  features  affected  by  these  confounders.
Statistical significance was set at 0.05 and adjusted for multiple comparisons.
Results
Participant clinical and demographic characteristics
LRRK2-PD  and  iPD  patients  were  of  similar  ages,  while  LRRK2-NMC  individuals  were
significantly younger (Table 1). Disease duration was significantly longer in LRRK2-PD than in
the iPD group, however no significant differences in the severity of motor signs (UPDRSIII)
were  found.  Symptoms  of  autonomic  dysfunction  (SCOPA-AUT)  were  significantly  more
frequent  in  LRRK2-PD patients  compared  to  controls,  although no significant  differences
were found in the cardiovascular subscale. Information regarding orthostatic hypotension
and L-dopa equivalent daily dose was not available for all patients.
Associations between HRV measures and clinical characteristics
HRV was not  associated with disease duration in any of  the PD groups.  Among the iPD
patients, only the global HRV measures (SDNN, W, CV, ASI, TP, and ShE), LF power, DC, and
AC  were  inversely  associated  with  UPDRSIII  (r≤|0.66|).  However,  no  associations  with
UPDRSIII were observed in LRRK2-PD. Among the LRRK2-PD patients, DC, AC and HF power
were inversely associated with the SCOPA-AUT total score (r≤|0.73|). The HRV measures DC
and AC were both highly correlated with rMSSD and HF power (r≤0 .92), and thus considered
beat-to-beat HRV measures. Among the healthy controls, age was weakly correlated with
most  HRV  features  but  not  correlated  with  RE.  RE  and  PE  features  provided  additional
information on HRV characteristics as they were weakly or not at all correlated with other
HRV measures. PE features and the ordinal pattern statistics that best distinguished LRRK2-
PD from controls showed no dependence on HR.
HRV in LRRK2-PD vs. controls
Generally, HRV values were greater in LRRK2-PD patients than in controls, although only the
beat-to-beat  measures  of  HRV,  i.e.,  rMSSD,  SD1,  HF,  DC,  and  AC,  reached  statistical
significance (Table 2, Supplementary Fig. 2). Consistent with this, a significant increase in
the irregularity of HR dynamics was verified in LRRK2-PD patients, as assessed through RE
features (Table 2). DC and RE revealed that 7% and 28% of LRRK2-PD patients (N=1 and
N=4, respectively) had standardized values outside the normal range (3–7, mean±2SD). PE
and  ordinal  pattern  analysis  also  revealed  an  increased  irregularity  and  altered  ordinal
structure  of  HR  dynamics  in  the  LRRK2-PD  patients,  which  were  statistically  significant
before correcting for multiple comparisons (e.g., p=0.031 and p=0.003, respectively). The
combination of  ordinal  pattern statistics,  which were poorly correlated and distinguished
LRRK2-PD from controls,  facilitated the identification of  cardiac  rhythm alterations  at  an
individual level (Fig. 1). The best classification functions performed with an overall accuracy,
sensitivity and specificity of 93% each (Supplementary Table 1).
HRV in LRRK2-PD vs. iPD
Most of the global HRV measures, LF power, and the beat-to-beat HRV measures DC and AC
were  significantly  greater  in  LRRK2-PD  compared  to  iPD,  although the  greatest  group
differences were seen in central moments and RE features (Table 2). Bradycardia (HR<60
bpm) associated with elevated deceleration capacity (DC>5.5) was found in 21% of LRRK2-
PD patients (N=3), compared to 4% of controls (N=1) and 5% of iPD patients (N=1) (p>0.05
in both cases). A pattern of periodic HR accelerations between periods of respiratory sinus
arrhythmia (Fig. 2) was also found in 21% of LRRK2-PD patients (N=3), compared to 4% of
controls (N=1) and 5% of iPD patients (N=1) (p>0.05 in both cases).
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5HRV in LRRK2-NMC vs. controls
Overall, HRV values in the LRRK2-NMC group were intermediate between those in controls
and LRRK2-PD patients, and no significant differences were found between LRRK2-NMC, RNC
and controls. However, there was an increase in the proportion of LRRK2-NMC individuals
with values of beat-to-beat HRV measures above the mean standardized interval (4.5–5.5),
as was found in the LRRK2-PD group (Fig. 3). Significant differences in the  distribution of
these features between LRRK2-NMC and controls were found only for HF power (p<0.05). By
analyzing  the  HRV  Z-scores  above  the  normal  range  in  LRRK2-NMC,  it  was  possible  to
identify  an  individual  who  satisfied  criteria  for  prodromal  LRRK2-PD  according  to  the
International  Parkinson  and  Movement  Disorder  Society  (see  Electronic  Supplementary
Material) (red bars in Fig. 3). However, not all of the LRRK2-NMC individuals showed high
values and a small percentage had values below the normal range for rMSSD and DC (purple
bars in Fig. 3).
The irregularity of HR dynamics as quantified by RE was found to be decreased in LRRK2-
NMC compared to RNC, before correcting for multiple comparisons (Supplementary Table 2).
However, the RE feature HR that best distinguished LRRK2-PD from controls, HR(-α,8) as seen
in Table 2, showed a higher proportion of values on both sides of its distribution in LRRK2-
NMC compared to controls, a pattern similar to that found for DC (Fig. 3). The subgroup of
LRRK2-NMC showing the highest DC and the lowest HR values (28%, N=7) overlapped with
the  individuals  in  the  LRRK2-PD  group  (Fig.  4).  Among  HRV  features,  central  moments
revealed the greatest differences in cardiac chronotropism among LRRK2-NMC and RNC or
LRRK2-PD (Supplementary Table 2). 
Discussion
In this study, we assessed cardiac autonomic modulation in carriers of the  LRRK2 G2019S
mutation  manifesting  and  non-manifesting  PD,  through  the  HRV  analysis  of  short-term
heartbeat interval sequences derived from EKGs recorded in a supine position. Our findings
indicated an altered autonomic modulation of cardiac chronotropy early in LRRK2-PD, as
suggested by consistent results obtained in both LRRK2-NMC and LRRK2-PD groups. These
alterations were different from the cardiac autonomic impairment described for iPD.
We found a significant increase in rMSSD and HF power in LRRK2-PD patients compared to
controls, which might suggest an overactive vagal system (Stein et al., 2005). These results
are consistent with the findings of a previous study, where a significant increase in both
diurnal  and  nocturnal  HF  power  was  reported  in  a  cohort  of  eight  Sardinian  LRRK2-PD
patients (Solla, 2013). Yet, in previous work reporting on a partially overlapping sample, we
found  no  significant  differences  in  rMSSD  or  HF  power  when  comparing  20  LRRK2-PD
patients with controls (Visanji et al., 2017), although mean values for these measures were
greater than controls in 10 LRRK2-PD patients (Goldman et al., 2014). Some of us recently
described  two  distinct  clinical-pathological  subtypes  of  G2019S-associated  PD,  one  with
typical  Lewy pathology and the other  devoid  of  this  brain  synucleinopathy  (Kalia  et  al.,
2015). The latter patients also had evidence for less severe ANS dysfunction. Consistent with
this earlier finding, we now report that among LRRK2-PD patients, a higher prevalence of
autonomic  symptoms is  associated  with  lower  markers  of  cardiac  vagal  activity.  Hence,
discrepancies  across  the  HRV  findings  from  LRRK2-PD  studies  could  reflect  the
neuropathologic heterogeneity of G2019S-associated PD. 
We extended our previous findings by integrating novel approaches to HRV analysis. DC and
RE were both significantly increased in the LRRK2-PD group compared to controls. In fact,
both measures in combination facilitated the identification of five LRRK2-PD patients with
abnormally high values of beat-to-beat variability and irregularity of HR. Furthermore, DC
and RE values tended to cluster  towards  both sides of  their  distribution in  LRRK2-NMC,
consistent with the existence of LRRK2-NMC subgroups as previously suggested (Dzamko et
al.,  2016).  Since  LRRK2-PD  is  characterized  by  incomplete  penetrance,  the  LRRK2-NMC
subgroup showing a higher DC and irregularity of HR might represent those in a preclinical
stage and thus at greater risk of developing PD, as was seen for the prodromal subject. DC
has  previously  been  shown  to  identify  patients  at  higher  risk  of  mortality  following
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6myocardial  infarction  (Bauer  et  al.,  2006).  Although  this  hypothesis  needs  testing  in
longitudinal studies, results  suggest that DC and RE are promising biomarkers that could
provide  prognostic  information  in  LRRK2-NMC, potentially  adding  to  the  list  of  clinical
conditions in which these features have proven useful  (Bauer et al., 2006; Cornforth et al.,
2014). 
A  further  novel  interpretation  is  a  differential  involvement  of  the  cholinergic  and
noradrenergic systems in LRRK2-PD and iPD. The novel HRV measures of vagal modulation,
DC and AC, were both elevated in LRRK2-PD compared to iPD and controls;  whereas LF
power, which reflects both vagal and sympathetic contributions to heart rate modulation,
was  similar  in  LRRK2-PD  compared  to  controls,  but  greater  compared  to  iPD.  These
autonomic  alterations  were associated  with  a  greater  global  HRV and HR irregularity  in
LRRK2-PD  compared  to  iPD,  further  suggesting  pathophysiological  differences  for  the
development of cardiac autonomic neuropathy between the two types of PD. Postganglionic
noradrenergic lesions are the main cause of cardiac dysautonomia in iPD (Goldstein, 2003),
whereas  impairment  of  central  vagal  feedback  loops  may  account  for  the  cardiac
chronotropic alterations found in LRRK2-PD. However, cardiac sympathetic denervation has
also  been  reported  in  LRRK2-PD  (Goldstein  et  al.,  2007).  Consistent  with  our  results,
decreased HRV and sympathetic involvement have both been found in iPD compared with
LRRK2-PD  (Tijero  et  al.,  2013;  Visanji  et  al.,  2017).  Furthermore,  increased  cholinergic
activity was recently reported in the brain of 14 LRRK2-PD and 16 LRRK2-NMC individuals
using positron emission tomography (Liu et al.).
Animal studies have provided evidence for pro-inflammatory cytokine activation of vagal
afferent signaling, which leads to excitatory synaptic transmission in the  nucleus tractus
solitarius and subsequent synaptic activation of efferent vagal pathways originating in the
nucleus ambiguus (Watkins et al., 1995), the main source of preganglionic parasympathetic
cardiac motoneurons (Geis & Wurster, 1980). Elevated peripheral pro-inflammatory markers
have been reported in LRRK2 G2019S mutation carriers (Brockmann et al., 2016; Dzamko et
al., 2016), whereas a central microglial pro-inflammatory response has been associated as
well with LRRK2 mutations (Berg et al., 2015). Previous studies have shown involvement of
the vagus nerve in attenuating release of  cytokines and downregulating systemic tumor
necrosis factor production,  providing evidence for a  cholinergic anti-inflammatory pathway
(Borovikova et al., 2000). Increased peripheral cholinergic drive, as was observed in LRRK2-
NMC  and  LRRK2-PD  individuals,  might  therefore  represent  an  early  and  sustained
compensatory mechanism to counter-balance the inflammation reported in these cohorts.
In summary, our findings are consistent with the results of previous work reporting i) greater
central cholinergic activity in  LRRK2 carriers both manifesting and non-manifesting PD (Liu
et al.), and ii) increased cardiac cholinergic activity in PD patients with the LRRK2 mutation
(Solla, 2013). Further study to clarify whether this central and peripheral hypercholinergic
activity is a G2019S mutation-related mechanism, which operates as a form of prodromal
compensation for LRRK2 immune activation and persists after PD becomes manifest, needs
to be addressed.
Limitations
The  study  patients  were  under  L-dopa  treatment,  which  may  have  affected  autonomic
regulation, although previous work have found no significant differences in cardiovascular
autonomic function between drug-naïve and dopaminergic drug treated iPD patients (Kim et
al., 2016; Turkka et al., 1987). Although HRV differences between groups were consistent,
larger sample sizes are required to further explore the heterogeneous presentation of PD.
Additional information might also be gained by using 24-hour Holter monitoring.
Conclusions
Our findings extend current knowledge of differences in the non-motor profile of LRRK2-PD
and  iPD.  The  LRRK2 G2019S  mutation  was  found  to  be  associated  with  a  significantly
increased  beat-to-beat  HRV,  presumably  of  cardiac  cholinergic  origin,  suggesting  that
modifications of central vagal feedback loops might occur in the preclinical, prodromal and
clinical stages of LRRK2-PD. Cardiac chronotropic alterations distinguished LRRK2-PD from
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7iPD patients,  supporting distinct pathological  mechanisms underlying both PD types.  Our
results raise the possibility that Rényi entropy and HRV measures of vagal modulation may
be relevant biomarkers of prodromal LRRK2-PD. Further research and longitudinal studies,
aimed at performing an integral evaluation of cardiovascular autonomic function in different
stages of LRRK2-PD, are needed to understand the full clinical importance of our findings.
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Table 1. Clinical features of participants
Feature Control LRRK2-PD
LRRK2-
PD vs.
Control
iPD
LRRK2-
PD vs.
iPD
NMC
NMC vs.
LRRK2-
PD
RNC NMC vs.RNC
N 27 14 - 20 - 25 - 32 -
Fem/Male 15/12 3/11 0.037 10/10 ns 8/17 ns 16/16 ns
Age (yrs) 58.7 ±
13.9
63.3 ±
10.8
ns 64.1 ±
10.8
ns 50.3 ±
13.6
0.004 45.2 ±
14.8
ns
HR (bpm) 69 ± 11 67 ± 10 ns 69 ± 7 ns 63 ± 9 ns 63 ± 10 ns
DD (yrs) na 10.8 ± 5.1 - 6.3 ± 6.0 0.015 na - na -
UPDRSIII 1.00 ±
3.00
16.70 ±
15.60
<0.0001 23.00 ±
12.00
ns 2.00 ±
4.85
<0.0001 0.00 ±
2.50
0.026
SCOPA-
AUT
8.53 ±
6.72
23.5 ±
13.2
0.0003 nd - 10.07 ±
5.13
0.001 8.23 ±
5.94
ns
Values  are  expressed  as  mean  ± standard  deviation  or  number  of  cases  (N).  UPDRSIII  score  is
expressed as median ± interquartile range. Sex differences were assessed using a Chi-Square test;
mean heart rate (HR) using a multiple regression analysis adjusted for age, sex and the effect of age
and sex interaction; age, log-transformed disease duration (DD), and SCOPA-AUT score using a t-test;
and UPDRSIII using a Mann-Whitney U test. DD: disease duration; Fem: female; HR: mean heart rate;
iPD: idiopathic Parkinson’s disease group; LRRK2-PD: LRRK2-associated Parkinson’s disease group; N:
number of cases; na: not applicable; nd: not determined; NMC: LRRK2-non-manifesting carriers group;
ns:  p≥0.05,  not  statistically  significant;  RNC:  related  non-carriers  group;  SCOPA-AUT:  Scales  for
Outcomes in Parkinson’s Disease-Autonomic; UPDRSIII: Unified Parkinson’s Disease Rating Scale part
3.
467
468
469
470
471
472
473
474
475
476
477
11
Table 2. Heart rate variability in Parkinson’s disease patients and healthy controls
Description Feature Control LRRK2-PD
LRRK2-
PD vs.
Control
iPD
LRRK2-
PD vs.
iPD
Overall HRV
LogSDNN 3.45 ± 0.46 3.51 ± 0.34 ns 3.19 ± 0.51 0.005
LogCV 1.27 ± 0.42 1.31 ± 0.33 ns 1.03 ± 0.45 0.005
LogASI 3.42 ± 0.91 3.30 ± 0.65 ns 3.89 ± 0.96 0.010
LogTP 2.44 ± 0.09 2.46 ± 0.07 ns 2.39 ± 0.10 0.047
H 5.69 ± 0.59 5.81 ± 0.43 ns 5.36 ± 0.65 0.001
LogMom
3
-1.23 ±
1.27
-1.91 ± 1.39 ns -1.05 ± 1.13 0.01
LogMom
4
1.25 ± 0.26 1.17 ± 0.33 ns 1.38 ± 0.38 0.0006
LogMom
5
1.18 ± 1.15 0.06 ± 1.68 ns 1.48 ± 1.12 0.003
LogMom
6
3.09 ± 0.68 2.77 ± 0.75 ns 3.32 ± 0.88 0.0004
LogMom
7
3.55 ± 1.33 2.19 ± 1.52 ns 3.87 ± 1.49 0.0008
LogMom
8
5.19 ± 1.13 4.57 ± 1.19 ns 5.52 ± 1.38 0.0003
LogMom
9
-5.90 ±
1.67
4.41 ± 2.01 ns 6.25 ± 1.96 0.0007
Beat-to-beat HRV
LogrMSS
D
2.92 ± 0.55 3.13 ± 0.40 0.015 2.80 ± 0.56 ns
LogHF 2.29 ± 0.12 2.32 ± 0.09 0.012 2.25 ± 0.12 ns
LogDC 1.98 ± 0.59 2.13 ± 0.47 0.006 1.68 ± 0.64 0.026
Log|AC| 1.97 ± 0.58 2.11 ± 0.42 0.012 1.71 ± 0.66 0.032
Intermediate-term 
HRV
LogLF 2.38 ± 0.10 2.40 ± 0.09 ns 2.32 ± 0.12 0.032
HR Irregularity
HR(-α,4) 1.29 ± 0.04 1.23 ± 0.06/1.05 ± 0.02
0.002
1.06 ± 0.02 0.009
HR(+α,4) 0.94 ± 0.02 0.95 ± 0.02 0.004 0.94 ± 0.02 ns
HR(-α,8) 1.24 ± 0.05 1.18 ± 0.07/1.05 ± 0.04
0.002
1.07 ± 0.04 0.001
HR(+α,8) 0.94 ± 0.02 0.96 ± 0.02 0.003 0.94 ± 0.03 ns
HR(-α,16) 1.12 ± 0.06 1.07 ± 0.05/1.04 ± 0.03
0.003
1.06 ± 0.04 0.0004
HR(+α,16
)
0.93 ± 0.02 0.95 ± 0.02/
0.98 ± 0.01
0.003
0.97 ± 0.01 0.0008
Table  2  shows  heart  rate  variability  (HRV)  values  for  the  LRRK2-associated  Parkinson’s  disease
(LRRK2-PD), idiopathic Parkinson’s disease (iPD), and control groups. Values are expressed as mean ±
standard  deviation.  Beat-to-beat  HRV  features  reflect  the  vagal  modulation  of  heart  rate  (HR),
whereas  the  remaining  features  may  reflect  the  contribution  of  both  vagal  and  sympathetic
modulation.  Group contrasts show p-values for mean HRV differences as assessed through multiple
regression analysis adjusted for age, sex, and  mean HR. The LRRK2-PD  vs. iPD contrasts were also
adjusted  for  disease  duration. Only  significant  values  at  p<0.05  are  shown.  P-values  remaining
significant after correcting for multiple comparisons appear in bold  text.  The best results of Rényi
entropy  HR calculated over  sequences of  length λ = 4,  8,  and 16 cardiac interbeat  intervals,  for
positive and negative order α are shown. As distinct  α  values may be used, the values of the  HR
revealing the greatest differences for the contrasts LRRK2-PD vs. Control and LRRK2-PD vs. iPD are
shown in that order.  Increased irregularity of HR changes is manifested as an increase in  HR with
positive order +α or as a decrease in HR with negative order -α. α: order of Rényi entropy, α={-5,-4,-
3,-2,-1,+1,+2,+3,+4,+5}; AC: acceleration capacity of heart rate; ASI: autonomic stress index; CV:
coefficient  of  variation  of  normal-to-normal  intervals;  DC:  deceleration  capacity  of  heart  rate;  H:
Shannon entropy; HR: Rényi entropy; HF: power spectral density of the high frequency band (0.15–0.4
Hz); LF: power spectral density of the low frequency band (0.04–0.15 Hz); Log: log-transformed value;
Mom3-Mom9: standardized central moments of heartbeat interval distribution of 3 rd to 9th order; ns:
p≥0.05, not statistically significant;  rMSSD: square root of the mean of the sum of the squares of
differences  between  adjacent  normal-to-normal  intervals;  SDNN:  standard  deviation  of  normal-to-
normal intervals; TP: power spectral density of the total power band (0.04–0.4 Hz).
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Fig. 1 Discrimination of LRRK2-associated Parkinson’s disease (LRRK2-PD) patients and 
healthy controls based on ordinal pattern statistics of heart rate. The discrimination of 
patients and controls based on the probabilities of ordinal pattern P1 and P2 achieved the best 
classification accuracy (discriminant model p<0.0001). P1 and P2 were calculated for patterns 
expanding four heartbeat intervals over the time scales 13 and 16, respectively. 
Fig. 2 Periodic heart rate accelerations in LRRK2-associated Parkinson’s disease (LRRK2-
PD). A, Tachogram of a LRRK2-PD patient showing heart rate accelerations (indicated by blue arrows)
separated by periods of respiratory sinus arrhythmia (one of these periods is illustrated by the blue 
tracing). B, Tachogram of a control participant comparable for age, sex, and mean heart rate to the 
patient in panel A. NN intervals are plotted vs. the interval order (horizontal axis). NN: normal-to-
normal cardiac interbeat interval.         
Fig. 3 Standardized distribution of beat-to-beat variability and irregularity measures of
heart  rate  dynamics  in  LRRK2-non-manifesting  carriers  (LRRK2-NMC). Standardized
distributions. Compared to controls, the mean interval (green bar) for rMSSD, HF, and AC is shortened
and shifted to the left in the LRRK2-NMC and LRRK2-PD groups, indicating a greater proportion of
values above the mean. For DC and HR, the mean interval in the LRRK2-NMC group is only shortened,
indicating a greater proportion of values below and above the mean. AC: acceleration capacity of
heart rate; DC: deceleration capacity of heart rate; HR: Rényi entropy; HF: power spectral density of
the high frequency band (0.15–0.4 Hz); rMSSD: square root of the mean of the sum of the squares of
differences between adjacent normal-to-normal intervals. 
Fig.  4  Subgroup of  LRRK2-non-manifesting  carriers  (LRRK2-NMC)  overlapping  with  the
LRRK2-associated Parkinson’s disease (LRRK2-PD) group.  The subgroup of LRRK2-NMC with
the highest DC and the lowest HR overlaps with the LRRK2-PD group. DC: deceleration capacity of
heart rate; HR: Rényi entropy. 
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